{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:31:40Z","timestamp":1759969900892,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.maturitas.2009.09.009","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T04:28:52Z","timestamp":1254889732000},"page":"172-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Managing hereditary ovarian cancer"],"prefix":"10.1016","volume":"64","author":[{"given":"M.J.","family":"Mourits","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2009.09.009_bib1","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z","article-title":"The genetic attributable risk of breast and ovarian cancer","volume":"77","author":"Claus","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10689-004-4489-x","article-title":"Evolution of the nomenclature for the hereditary colorectal cancer syndromes","volume":"4","author":"Boland","year":"2005","journal-title":"Fam Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1053\/gast.1996.v110.pm8612988","article-title":"Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis","volume":"110","author":"Vasen","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.maturitas.2009.09.009_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10689-007-9164-6","article-title":"Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)","volume":"7","author":"Geary","year":"2008","journal-title":"Fam Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#","article-title":"Extracolonic cancer in hereditary nonpolyposis colorectal cancer","volume":"71","author":"Watson","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","article-title":"ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome","volume":"113","author":"American College of Obstetricians and Gynecologists","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/AOG.0b013e318195ad17","article-title":"The accuracy of risk scores in predicting ovarian malignancy: a systematic review","volume":"113","author":"Geomini","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib9","first-page":"70","article-title":"Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy","volume":"78","author":"Sassone","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/gyno.1993.1239","article-title":"Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center","volume":"51","author":"Muto","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","article-title":"Surveillance of women at high risk for hereditary ovarian cancer is inefficient","volume":"94","author":"Oei","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.bjc.6603408","article-title":"High percentage of abnormal findings on TVU needs further discussion","volume":"95","author":"Mourits","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jacr.2007.07.006","article-title":"Evaluating adnexal lesions: which need follow-up?","volume":"4","author":"Miller","year":"2007","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e31816ddb6f","article-title":"Ovarian status in healthy postmenopausal women","volume":"15","author":"Healy","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2009.09.009_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/uog.212","article-title":"Frequency and type of adnexal lesions in autopsy material in postmenopausal women: ultrasound study with histological correlation","volume":"22","author":"Valentin","year":"2003","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/bmj.306.6884.1025","article-title":"Screening for early ovarian cancer with transvaginal ultrasonography and colour Doppler blood flow imaging","volume":"306","author":"Bourne","year":"1993","journal-title":"Br Med J"},{"key":"10.1016\/j.maturitas.2009.09.009_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0090-8258(03)00414-1","article-title":"Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography","volume":"91","author":"Ueland","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","article-title":"Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125","volume":"2","author":"Kabawat","year":"1983","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2009.09.009_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/80.3.208","article-title":"Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma","volume":"80","author":"Mann","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.09.009_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2009.09.009_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","article-title":"Prevention and early detection of ovarian cancer: mission impossible?","volume":"174","author":"Bast","year":"2007","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.maturitas.2009.09.009_bib23","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1200\/JCO.2005.03.909","article-title":"Screening for familial ovarian cancer: the need for well-designed prospective studies","volume":"23","author":"Jacobs","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2009.09.009_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/01443610500378616","article-title":"Ovarian cancer death reduction for women at high risk: workload implications for gynaecology services","volume":"26","author":"Hannemann","year":"2006","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ygyno.2007.08.009","article-title":"Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer","volume":"107","author":"Zhang","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2009.09.009_bib28","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1002\/pmic.200601044","article-title":"Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications","volume":"7","author":"Liu","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.maturitas.2009.09.009_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajog.2008.04.009","article-title":"The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?","volume":"199","author":"Nossov","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","article-title":"Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?","volume":"124","author":"Van der Velde","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib31","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1471-0528.2007.01499.x","article-title":"Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective","volume":"114","author":"Woodward","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.maturitas.2009.09.009_bib32","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ygyno.2006.06.032","article-title":"Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study","volume":"103","author":"Bosse","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ijgc-00009577-200602001-00009","article-title":"Efficacy of screening at high risk of hereditary ovarian cancer: results of an 11-year cohort study","volume":"16","author":"Gaarenstroom","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2005.08.038","article-title":"CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer","volume":"100","author":"Olivier","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejca.2004.10.029","article-title":"Early detection of breast and ovarian cancer in families with BRCA mutations","volume":"41","author":"Vasen","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ygyno.2005.01.024","article-title":"Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer","volume":"97","author":"Meeuwissen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib37","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1200\/JCO.2005.05.097","article-title":"Screening for familial ovarian cancer failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system","volume":"23","author":"Stirling","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ijgc-00009577-200201000-00014","article-title":"Use of CA-125 and ultrasound in high-risk women","volume":"12","author":"Laframboise","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib39","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.2002.20.5.1260","article-title":"Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers","volume":"20","author":"Scheuer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1034\/j.1600-0412.1999.781013.x","article-title":"Prospectively detected cancer in familial breast\/ovarian cancer screening","volume":"78","author":"D\u00f8rum","year":"1999","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.maturitas.2009.09.009_bib41","article-title":"Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers","author":"Evans","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.maturitas.2009.09.009_bib42","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2009.09.009_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2009.03.015","article-title":"The temporal stability of the Symptom Index among women at high-risk for ovarian cancer","author":"Lowe","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib45","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2009.09.009_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.09.009_bib47","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2003.09.052","article-title":"Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation","volume":"21","author":"Meijers-Heijboer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib48","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.22817","article-title":"Effectiveness of preventive interventions in BRCA1\/2 gene mutation carriers: a systematic review","volume":"121","author":"Bermejo-P\u00e9rez","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2009.09.009_bib49","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-08-1387","article-title":"Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterisation of mismatch repair deficient tumor histology","volume":"14","author":"Pal","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.maturitas.2009.09.009_bib50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2004.01.010","article-title":"Letter commenting on \u201cPatholologic finding in prophylactic oophorectomy specimens in high-risk women\u201d (87:52\u20136) by Pamela Paley, et al.","volume":"93","author":"Mourits","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2009.09.009_bib52","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON and the IBCCS Collaboration Group","volume":"25","author":"Brohet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2009.09.009_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1\/2 Carriers Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2009.09.009_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ajmg.a.30635","article-title":"Place of preimplantation diagnosis in genetic practice","volume":"134A","author":"Kuliev","year":"2005","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.maturitas.2009.09.009_bib56","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib57","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.09.009_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2009.09.009_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"Von Schoultz","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2009.09.009_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-008-0138-7","article-title":"Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study","volume":"115","author":"Buijs","year":"2009","journal-title":"Breast Cancer Res Treat"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209003235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209003235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:46:44Z","timestamp":1759913204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512209003235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0378512209003235"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.09.009","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing hereditary ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}